Resumen
Evolving modes of ultrasound-based elastography have achieved promising validity and reliability for evaluating liver fibrosis. Liver stiffness (LS) is a valuable biomarker for modeling liver disease progression and regression on a continuous noncategorical scale as changes in LS per year or for determining the LS progression or regression rate for refining LS measurement (LSM)-based prognostics. The paradigm of LSMs has altered the focus from liver fibrosis staging alone to comprehensive liver-relevant risk estimations. However, diverse ranges of cohort characteristics, disease types, surveillance protocols and timeframes, necroinflammatory resolutions or biochemical responses (BRs), factors explaining the magnitude or kinetics in LS change, virologic responses (VRs), fibrosis reversals (FRs), and noninvasive surveillance results have rarely been reviewed collectively. Elastography-based LS surveillance alone conveys chronological and valuable patient information and assists in characterizing worldwide patient cohorts under antiviral treatment by delineating the concurrent time elapsed, VR, BR, and FR. In groups with uniform VRs to direct-acting antivirals for chronic hepatitis C and nucleoside and nucleotide analogs for chronic hepatitis B, decline in LS can be explained using concurrent BR from 24 weeks to 3 years, followed by FR and the time elapsed.